UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 122

Sortiert nach

BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer

Annals of oncology, 2013-11, Vol.24 Suppl 8, p.viii22-viii27

Pothuri, B

2013

Volltextzugriff (PDF)

Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement: This practice statement has been endorsed by The North American Menopause Society

Gynecologic oncology, 2020-05, Vol.157 (2), p.303-306

2020

Volltextzugriff (PDF)

Immunotherapy toxicities: An SGO clinical practice statement

Gynecologic oncology, 2022-07, Vol.166 (1), p.25-35

2022

Volltextzugriff (PDF)

Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO)

Gynecologic oncology, 2023-07, Vol.174, p.278-287

2023

Volltextzugriff (PDF)

Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial

Annals of oncology, 2024-08, Vol.35 (8), p.728-738

2024

Volltextzugriff (PDF)

131P Frequency of germline testing after tumor sequencing by cancer type

Annals of oncology, 2022-09, Vol.33, p.S597

2022

Volltextzugriff (PDF)

A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: Blinded pooled interim safety data from the PRIMA Study

Annals of oncology, 2018-10, Vol.29, p.viii335-viii336

2018

Volltextzugriff (PDF)

Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer

Annals of oncology, 2012-12, Vol.23 (12), p.3104-3110

2012

Volltextzugriff (PDF)

A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD + advanced ovarian cancer after response to front-line platinum-based chemotherapy

Gynecologic oncology, 2017-06, Vol.145, p.98-98

2017

Volltextzugriff (PDF)

Safety of robotic-assisted gynecologic surgery and early hospital discharge in elderly patients

Gynecologic oncology, 2017-06, Vol.145, p.178-178

2017

Volltextzugriff (PDF)

How old is too old: Safety of minimally invasive gynecologic surgery and early hospital discharge in the oldest elderly

Gynecologic oncology, 2017-06, Vol.145, p.140-141

2017

Volltextzugriff (PDF)

Indication for robotic-assisted surgery influences perioperative outcomes and hospital readmissions among women undergoing gynecologic procedures

Gynecologic oncology, 2017-06, Vol.145, p.145-146

2017

Volltextzugriff (PDF)

Reoperation and recurrence rates in women undergoing conservative surgery for low malignant potential tumors

Gynecologic oncology, 2017-06, Vol.145, p.39-39

2017

Volltextzugriff (PDF)

Prospective evaluation of a facilitated referral pathway to improve uptake of genetic assessment for women with newly diagnosed ovarian cancer

Gynecologic oncology, 2017-06, Vol.145, p.149-150

2017

Volltextzugriff (PDF)

231 Utilization of immunotherapy among eligible patients with cervical cancer

International journal of gynecological cancer, 2020-11, Vol.30 (Suppl 3), p.A95-A95

2020

Volltextzugriff (PDF)

Predictors of port site hernia necessitating operative intervention in patients undergoing robotic surgery

Gynecologic oncology, 2017-06, Vol.145, p.176-176

2017

Volltextzugriff (PDF)

Abstract number 14: mTOR complex inhibition as a novel therapeutic strategy in high grade papillary serous ovarian cancer

Gynecologic oncology, 2014-08, Vol.134 (2), p.434-435

2014

Volltextzugriff (PDF)

Trial design and endpoint definition for conservative management of endometrial neoplasia

Gynecologic oncology, 2013-07, Vol.130 (1), p.e66-e66

2013

Volltextzugriff (PDF)

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

The New England journal of medicine, 2019-12, Vol.381 (25), p.2391-2402

2019

Volltextzugriff (PDF)

mTOR complex inhibition as a novel therapeutic strategy in high-grade papillary serous ovarian cancer

Gynecologic oncology, 2014-06, Vol.133, p.119-120

2014

Volltextzugriff (PDF)

Cross-sectional study on the impact of a natural disaster on delivery of gynecologic oncology care

Gynecologic oncology, 2014-06, Vol.133, p.150-150

2014

Volltextzugriff (PDF)

The Effect of Hematologic Malignancies on Perioperative Transfusions for Patients Undergoing Hysterectomy

Journal of minimally invasive gynecology, 2023-11, Vol.30 (11), p.S6-S7

2023

Volltextzugriff (PDF)

Survey of physician awareness of oocyte and embryo cryopreservation in women with hereditary breast ovarian cancer (HBOC) syndrome

Gynecologic oncology, 2012-03, Vol.125, p.S111-S112

2012

Volltextzugriff (PDF)

BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer: Hereditary breast and ovarian cancers: lessening the burden

Annals of oncology, 2013, Vol.24

POTHURI, B

2013

Volltextzugriff (PDF)

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

The New England journal of medicine, 2023-06, Vol.388 (23), p.2145-2158

2023

Volltextzugriff (PDF)

1 – 25 von 122

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(115)
Mit Volltextzugriff
(106)

Publikationsform

Sprache

Englisch
(120)
Japanisch
(5)
Deutsch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(24)
Life Sciences & Biomedicine
(21)
Hematology, Oncology And Palliative Medicine
(18)
Obstetrics And Gynecology
(18)
Female
(14)
Humans
(14)
Oncology
(14)
Obstetrics & Gynecology
(11)
Tumors
(11)
Middle Aged
(9)
Aged
(8)
Chemotherapy
(8)
Endometrial Cancer
(8)
Adult
(7)
Biological And Medical Sciences
(7)
Medical Sciences
(7)
Ovarian Cancer
(7)
Female Genital Diseases
(6)
Foraminifera
(6)
Gynecology. Andrology. Obstetrics
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer

Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement: This practice statement has been endorsed by The North American Menopause Society

Immunotherapy toxicities: An SGO clinical practice statement

Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO)

Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial

131P Frequency of germline testing after tumor sequencing by cancer type

A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: Blinded pooled interim safety data from the PRIMA Study

Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer

A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD + advanced ovarian cancer after response to front-line platinum-based chemotherapy

Safety of robotic-assisted gynecologic surgery and early hospital discharge in elderly patients

How old is too old: Safety of minimally invasive gynecologic surgery and early hospital discharge in the oldest elderly

Indication for robotic-assisted surgery influences perioperative outcomes and hospital readmissions among women undergoing gynecologic procedures

Reoperation and recurrence rates in women undergoing conservative surgery for low malignant potential tumors

Prospective evaluation of a facilitated referral pathway to improve uptake of genetic assessment for women with newly diagnosed ovarian cancer

231 Utilization of immunotherapy among eligible patients with cervical cancer

Predictors of port site hernia necessitating operative intervention in patients undergoing robotic surgery

Abstract number 14: mTOR complex inhibition as a novel therapeutic strategy in high grade papillary serous ovarian cancer

Trial design and endpoint definition for conservative management of endometrial neoplasia

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

mTOR complex inhibition as a novel therapeutic strategy in high-grade papillary serous ovarian cancer

Cross-sectional study on the impact of a natural disaster on delivery of gynecologic oncology care

The Effect of Hematologic Malignancies on Perioperative Transfusions for Patients Undergoing Hysterectomy

Survey of physician awareness of oocyte and embryo cryopreservation in women with hereditary breast ovarian cancer (HBOC) syndrome

BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer: Hereditary breast and ovarian cancers: lessening the burden

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

Suchergebnisse filtern